India Pharma Outlook Team | Tuesday, 26 August 2025
Merck, known as MSD outside the U.S. and Canada, will present new clinical trial and outcomes research results at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain, from August 29 – September 1. The statistics emphasize Merck’s research in atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction.
“Cardiovascular diseases remains the leading cause of death worldwide, and Merck is committed to addressing this urgent public health challenge through research and innovative science,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “At this year’s congress, the data we are presenting reflect our continued commitment to advancing cardiovascular research with the goal of improving outcomes for patients at risk around the world.”
Merck will present two oral presentations, both on treatment patterns and patient burden in patients with ASCVD. The first evaluates the clinical and economic burden on populations with and without myocardial infarction using a nationwide 10-year registry; the second reviews trends in lipid-lowering therapy utilization in patients with ASCVD. These studies will articulate potential opportunities for improved disease management in the real-world setting.
Also Read: Bayer Pharma to Launch New Drugs, Expanding Cardiology & Women's Health
Key developments will also be presented on WINREVAIR in pulmonary hypertension. This includes the rationale and design of the Phase 2 CADENCE study in adults with combined post- and precapillary PH linked to heart failure with preserved ejection fraction (HFpEF), and results from the ZENITH trial evaluating WINREVAIR’s effect on hemodynamics in high-risk pulmonary arterial hypertension (PAH).
